Tessera Therapeutics Highlights Advances Across In Vivo Programs for Sickle Cell Disease and T-Cell Therapies at the 66th American Society of Hematology Annual Meeting
December 09, 2024 12:05 ET | Source: Tessera Therapeutics In vivo proof-of-concept…
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
Poster presentation at ASH on Monday, December 9 at 6:00 p.m. PT…